<DOC>
	<DOC>NCT02197078</DOC>
	<brief_summary>This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.</brief_summary>
	<brief_title>Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: A dispensing of an oral hypoglycemic medication A diagnosis of type 2 diabetes mellitus (T2DM) Exclusion criteria: less than 18 years old missing or ambiguous age or sex information at least one diagnosis of type 1 diabetes mellitus less than 6 months enrolment in the database preceding the date of the first dispensing secondary diabetes history of cancer endstage renal disease (ESRD) HIV organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>